PATH is a global organization that works to accelerate health equity by bringing together public institutions, businesses, social enterprises, and investors to solve the world’s most pressing health challenges. With expertise in science, health, finance, technology, advocacy, and dozens of other specialties, PATH develops and scales innovative solutions—including vaccines, drugs, devices, diagnostics, and approaches to strengthening health systems worldwide.
In line with this, PATH has partnered with the government of Ethiopia and has built strong relationships with other partners working on Health endeavors since 2007. To mention one, it has gone so far in supporting the malaria control and elimination efforts of the country through one of its projects called MACEPA, which stands for Malaria Control and Elimination Partnership in Africa.
PATH is planning to implement a five-year project entitled “VivAccess” with the major objective of accelerating access to Plasmodium vivax (Pv) safer radical cure. Safer radical cure refers to the combination of appropriate drugs and a G6PD diagnostic test administered when treating a Pv malaria patient. The current drug regimen required to treat Pv can cause hemolysis in individuals who have a genetic disorder G6PD deficiency. It is therefore important to test people for G6Pd deficiency before administering liver-stage drugs, especially in geographies known for the stated genetic disorder.
The project will seek to engage and mobilize existing resources and local expertise to strengthen systems and implement best practices to facilitate sustainable scale-up and impact on malaria elimination endeavors in the country.